Please login to the form below

Not currently logged in
Email:
Password:

Cancer drug, Oxaliplatin, approved for UK

Colon and rectum cancer drug, Oxaliplatin, has been approved for use in the UK

Onco Therapies Ltd (OTL), a subsidiary of Strides Arcolab, has announced that its colon and rectum cancer drug, Oxaliplatin, has been approved through a decentralised procedure for use in the UK. Approval across other European countries is expected shortly.

The drug will be manufactured at Strides' oncology complex in Bangalore, India, and used to treat advanced cancer of the colon and rectum in combination with other medicines to slow or stop cancer cell growth. It will be administered as a 5mg/ml injection.

Oxaliplatin is one of 37 drugs licensed to Pfizer on a semi-exclusive basis for sales in 17 European countries.

This is the second European approval out of 22 filings made by the OTL in 2010, for products with a combined market value of over $5bn.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics